{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:46:37Z","timestamp":1792273597295,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00198-026-07941-7","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:14:10Z","timestamp":1773692050000},"page":"1729-1744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress of drug-induced osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Wenbin","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"7941_CR1","first-page":"8","volume":"20","author":"J Pizzorno","year":"2021","unstructured":"Pizzorno J, Pizzorno L (2021) Commonly prescribed and over-the-counter drugs as secondary causes of osteoporosis\u2014part two. Integr Med (Encinitas) 20:8\u201314","journal-title":"Integr Med (Encinitas)"},{"key":"7941_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1498-0","volume":"10","author":"L Han","year":"2019","unstructured":"Han L, Wang B, Wang R et al (2019) The shift in the balance between osteoblastogenesis and adipogenesis of mesenchymal stem cells mediated by glucocorticoid receptor. Stem Cell Res Ther 10:377. https:\/\/doi.org\/10.1186\/s13287-019-1498-0","journal-title":"Stem Cell Res Ther"},{"key":"7941_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065814","volume":"24","author":"L-T Wang","year":"2023","unstructured":"Wang L-T, Chen L-R, Chen K-H (2023) Hormone-related and drug-induced osteoporosis: a cellular and molecular overview. Int J Mol Sci 24:5814. https:\/\/doi.org\/10.3390\/ijms24065814","journal-title":"Int J Mol Sci"},{"key":"7941_CR4","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1007\/s10067-020-05554-x","volume":"40","author":"M Kawazoe","year":"2021","unstructured":"Kawazoe M, Kaneko K, Nanki T (2021) Glucocorticoid therapy suppresses Wnt signaling by reducing the ratio of serum Wnt3a to Wnt inhibitors, sFRP-1 and Wif-1. Clin Rheumatol 40:2947\u20132954. https:\/\/doi.org\/10.1007\/s10067-020-05554-x","journal-title":"Clin Rheumatol"},{"key":"7941_CR5","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.4187\/respcare.10933","volume":"68","author":"N Zhang","year":"2023","unstructured":"Zhang N, Fan X, Zhang Y et al (2023) Risk of fracture and osteoporosis in patients with COPD and inhaled corticosteroids treatment. Respir Care 68:1719\u20131727. https:\/\/doi.org\/10.4187\/respcare.10933","journal-title":"Respir Care"},{"key":"7941_CR6","doi-asserted-by":"publisher","unstructured":"Tan WB, Li J, Liu MY et al (2024) Secondary osteoporosis and respiratory diseases: an update. Chin J Endocrinol Metab 40:177\u2013182. (in Chinese).\u00a0https:\/\/doi.org\/10.3760\/cma.j.cn311282-20230915-00080","DOI":"10.3760\/cma.j.cn311282-20230915-00080"},{"key":"7941_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2021","volume":"30","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles M, Auladell-Rispau A, Monteagudo M et al (2021) Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev 30:210075. https:\/\/doi.org\/10.1183\/16000617.0075-2021","journal-title":"Eur Respir Rev"},{"key":"7941_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/art.42646","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI et al (2023) 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid\u2010induced osteoporosis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42646","journal-title":"Arthritis Rheumatol"},{"key":"7941_CR9","doi-asserted-by":"publisher","unstructured":"Watanabe H, Sugiyama K, Otsuji N, et al (2023) Effect of inhaled corticosteroids on bone mineral density in patients with asthma. Asian Pac J Allergy Immunol 41:45\u201352. https:\/\/doi.org\/10.12932\/AP-191019-0663","DOI":"10.12932\/AP-191019-0663"},{"key":"7941_CR10","doi-asserted-by":"publisher","unstructured":"Blavnsfeldt A-BG, Thurah A, de Thomsen MD et al (2018) The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials. Bone 114:172\u2013180. https:\/\/doi.org\/10.1016\/j.bone.2018.06.008","DOI":"10.1016\/j.bone.2018.06.008"},{"key":"7941_CR11","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3969\/j.issn.0253-9926.2019.16.039","volume":"48","author":"M Li","year":"2019","unstructured":"Li M, Cao Y, Feng WX, Feng WQ (2019) Effects of long-term use of proton pump inhibitors on osteoporosis in elderly patients with peptic ulcer. Shanxi Med J 48:2040\u20132042. (in Chinese).\u00a0https:\/\/doi.org\/10.3969\/j.issn.0253-9926.2019.16.039","journal-title":"Shanxi Med J"},{"key":"7941_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00774-015-0699-6","volume":"34","author":"E Bahtiri","year":"2016","unstructured":"Bahtiri E, Islami H, Hoxha R et al (2016) Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab 34:571\u2013579. https:\/\/doi.org\/10.1007\/s00774-015-0699-6","journal-title":"J Bone Miner Metab"},{"key":"7941_CR13","doi-asserted-by":"publisher","unstructured":"Roux C, Briot K, Gossec L et al (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13\u201319. https:\/\/doi.org\/10.1007\/s00223-008-9188-4","DOI":"10.1007\/s00223-008-9188-4"},{"key":"7941_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00583","volume":"11","author":"AAM Shaalan","year":"2020","unstructured":"Shaalan AAM, El-Sherbiny M, El-Abaseri TB et al (2020) Supplement with calcium or alendronate suppresses osteopenia due to long term rabeprazole treatment in female mice: influence on bone TRAP and osteopontin levels. Front Pharmacol 11:583. https:\/\/doi.org\/10.3389\/fphar.2020.00583","journal-title":"Front Pharmacol"},{"key":"7941_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.bone.2015.08.024","volume":"81","author":"MMC van der Hoorn","year":"2015","unstructured":"van der Hoorn MMC, Tett SE, de Vries OJ et al (2015) The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone 81:675\u2013682. https:\/\/doi.org\/10.1016\/j.bone.2015.08.024","journal-title":"Bone"},{"key":"7941_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3760\/cma.j.issn.1001-9030.2014.07.012","volume":"31","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhou X, Qian MJ, Tang W (2014) The effect of esomeprazole use to bone mineral density and bone metabolism of male rats. Chin J Exp Surg 31:1428\u20131430. https:\/\/doi.org\/10.3760\/cma.j.issn.1001-9030.2014.07.012","journal-title":"Chin J Exp Surg"},{"key":"7941_CR17","doi-asserted-by":"publisher","unstructured":"Adachi Y, Shiota E, Matsumata T et al (1998) Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 62:283\u2013285. https:\/\/doi.org\/10.1007\/s002239900431","DOI":"10.1007\/s002239900431"},{"key":"7941_CR18","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"Y-X Yang","year":"2006","unstructured":"Yang Y-X, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947\u20132953. https:\/\/doi.org\/10.1001\/jama.296.24.2947","journal-title":"JAMA"},{"key":"7941_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-023-03670-z","volume":"23","author":"M Gulec","year":"2023","unstructured":"Gulec M, Tassoker M, Erturk M (2023) Evaluation of cortical and trabecular bone structure of the mandible in patients using L-Thyroxine. BMC Oral Health 23:886. https:\/\/doi.org\/10.1186\/s12903-023-03670-z","journal-title":"BMC Oral Health"},{"key":"7941_CR20","doi-asserted-by":"publisher","unstructured":"Gonzalez Rodriguez E, Stuber M, Del Giovane C, et al (2020) Skeletal effects of levothyroxine for subclinical hypothyroidism in older adults: a TRUST randomized trial nested study. J Clin Endocrinol Metab 105:dgz058. https:\/\/doi.org\/10.1210\/clinem\/dgz058","DOI":"10.1210\/clinem\/dgz058"},{"key":"7941_CR21","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1002\/cam4.3200","volume":"9","author":"F Hawkins Carranza","year":"2020","unstructured":"Hawkins Carranza F, Guadalix Iglesias S, Luisa De Mingo Dom\u00ednguez M et al (2020) Trabecular bone deterioration in differentiated thyroid cancer: impact of long\u2010term TSH suppressive therapy. Cancer Med 9:5746\u20135755. https:\/\/doi.org\/10.1002\/cam4.3200","journal-title":"Cancer Med"},{"key":"7941_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5603\/EP.a2019.0049","volume":"71","author":"D Bin-Hong","year":"2020","unstructured":"Bin-Hong D, Fu-Man D, Yu L et al (2020) Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy. Endokrynol Pol 71:15\u201320. https:\/\/doi.org\/10.5603\/EP.a2019.0049","journal-title":"Endokrynol Pol"},{"key":"7941_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3961\/jpmph.2014.47.1.36","volume":"47","author":"Y-J Ko","year":"2014","unstructured":"Ko Y-J, Kim JY, Lee J et al (2014) Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health 47:36\u201346. https:\/\/doi.org\/10.3961\/jpmph.2014.47.1.36","journal-title":"J Prev Med Public Health"},{"key":"7941_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2238","volume":"342","author":"MR Turner","year":"2011","unstructured":"Turner MR, Camacho X, Fischer HD et al (2011) Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 342:d2238. https:\/\/doi.org\/10.1136\/bmj.d2238","journal-title":"BMJ"},{"key":"7941_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/jbmr.3407","volume":"33","author":"DW Shin","year":"2018","unstructured":"Shin DW, Suh B, Lim H et al (2018) J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. J Bone Miner Res 33:1037\u20131043. https:\/\/doi.org\/10.1002\/jbmr.3407","journal-title":"J Bone Miner Res"},{"key":"7941_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adi7861","volume":"17","author":"H Kalyanaraman","year":"2024","unstructured":"Kalyanaraman H, Casteel DE, China SP et al (2024) A plasma membrane\u2013associated form of the androgen receptor enhances nuclear androgen signaling in osteoblasts and prostate cancer cells. Sci Signal 17:eadi7861. https:\/\/doi.org\/10.1126\/scisignal.adi7861","journal-title":"Sci Signal"},{"key":"7941_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3760\/cma.j.cn311282-20200914-00633","volume":"36","author":"Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Medical Association (2020) Guldeline for diagnosis and treatment of osteoprosis in men. Chin J Osteoporos Bone Miner Res 36:817\u2013827.(in Chinese)\u00a0https:\/\/doi.org\/10.3760\/cma.j.cn311282-20200914-00633","journal-title":"Chin J Osteoporos Bone Miner Res"},{"key":"7941_CR28","doi-asserted-by":"publisher","unstructured":"Lin W-L, Hsieh Y-W, Lin C-L et al (2015) A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia Clin Endocrinol (Oxf) 82:503\u2013508. https:\/\/doi.org\/10.1111\/cen.12599","DOI":"10.1111\/cen.12599"},{"key":"7941_CR29","doi-asserted-by":"publisher","unstructured":"Rosen H, Tollin S, Balena R, Middlebrooks V, Moses A, Yamamoto M, Zeind A, Greenspan S (1995) Bone density is normal in male rats treated with finasteride. Endocrinology 136(4):1381\u20131387. https:\/\/doi.org\/10.1210\/endo.136.4.7895648","DOI":"10.1210\/endo.136.4.7895648"},{"key":"7941_CR30","doi-asserted-by":"publisher","unstructured":"Matzkin H, Chen J, Weisman Y et al (1992) Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf) 37:432\u2013436 https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb02355.x","DOI":"10.1111\/j.1365-2265.1992.tb02355.x"},{"key":"7941_CR31","doi-asserted-by":"publisher","unstructured":"Amory J, Anawalt B, Matsumoto A, Page S, Bremner W, Wang C, Swerdloff R, Clark R (2008) The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 179(6):2333\u20132338. https:\/\/doi.org\/10.1016\/j.juro.2008.01.145","DOI":"10.1016\/j.juro.2008.01.145"},{"key":"7941_CR32","unstructured":"Ma\u010dukat IR, Spanjol J, Orli\u010d ZC et al (2014) The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia Coll Antropol 38:835\u2013839"},{"key":"7941_CR33","unstructured":"Fan B, Zhang P, Li X-y (2012) Analysis on effect of finasteride on bone metabolism and bone mineral density in aged patients with benign prostate hyperplasia. Clin Focus 27:2142\u20132144. https:\/\/doi.org\/CNKI:SUN:LCFC.0.2012-24-010. (in Chinese)"},{"key":"7941_CR34","doi-asserted-by":"publisher","unstructured":"Angrimani D, Brito M, Rui B, Nichi M, Vannucchi C (2020) Reproductive and endocrinological effects of benign prostatic hyperplasia and finasteride therapy in dogs. Sci Rep 10(1). https:\/\/doi.org\/10.1038\/s41598-020-71691-7","DOI":"10.1038\/s41598-020-71691-7"},{"key":"7941_CR35","doi-asserted-by":"publisher","unstructured":"Li WB, Yang C, Liao Q et al (2024) Efficacy of epristeride versus finasteride in the treatment of patients with benign prostatic hyperplasia and their effects on serum hormone levels. Chin J Clin 52:1036\u20131039. https:\/\/doi.org\/10.3969\/j.issn.2095-8552.2024.09.009. (in Chinese)","DOI":"10.3969\/j.issn.2095-8552.2024.09.009"},{"key":"7941_CR36","doi-asserted-by":"publisher","unstructured":"Rosenberg E, B\u016f\u017ekov\u00e1 P, Fink H, Robbins J, Shores M, Matsumoto A, Mukamal K (2021) Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: the cardiovascular health study. Metabolism 114:154399. https:\/\/doi.org\/10.1016\/j.metabol.2020.154399","DOI":"10.1016\/j.metabol.2020.154399"},{"key":"7941_CR37","doi-asserted-by":"publisher","unstructured":"Yarrow JF, Phillips EG, Conover CF et al (2017) Testosterone plus finasteride prevents bone loss without prostate growth in a rodent spinal cord injury model. J Neurotrauma 34:2972\u20132981. https:\/\/doi.org\/10.1089\/neu.2016.4814","DOI":"10.1089\/neu.2016.4814"},{"key":"7941_CR38","doi-asserted-by":"publisher","unstructured":"Wen HN, Song M, Wang K et al (2020) Research progress on the relationship between psychotropic drugs and bone metabolism. J Tianjin Univ Tradit Chin Med 39:716\u2013720. https:\/\/doi.org\/10.11656\/j.issn.1673-9043.2020.06.23. (in Chinese)","DOI":"10.11656\/j.issn.1673-9043.2020.06.23"},{"key":"7941_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/cer-2018-0085","volume":"8","author":"DL Brinton","year":"2019","unstructured":"Brinton DL, Simpson AN, Fominaya CE, LaRue AC (2019) Impact of selective serotonin reuptake inhibitors in the veteran population: 10-year risk outcomes. J Comp Eff Res 8:431\u2013440. https:\/\/doi.org\/10.2217\/cer-2018-0085","journal-title":"J Comp Eff Res"},{"key":"7941_CR40","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/jbmr.3045","volume":"32","author":"V Bradaschia-Correa","year":"2017","unstructured":"Bradaschia-Correa V, Josephson AM, Mehta D et al (2017) The selective serotonin reuptake inhibitor fluoxetine directly inhibits osteoblast differentiation and mineralization during fracture healing in mice. J Bone Miner Res 32:821\u2013833. https:\/\/doi.org\/10.1002\/jbmr.3045","journal-title":"J Bone Miner Res"},{"key":"7941_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.biopsych.2012.11.003","volume":"74","author":"JM Hodge","year":"2013","unstructured":"Hodge JM, Wang Y, Berk M et al (2013) Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry 74:32\u201339. https:\/\/doi.org\/10.1016\/j.biopsych.2012.11.003","journal-title":"Biol Psychiatry"},{"key":"7941_CR42","doi-asserted-by":"publisher","unstructured":"Ak E, Bulut SD, Bulut S et al (2015) Evaluation of the effect of selective serotonin reuptake inhibitors on bone mineral density: an observational cross-sectional study. Osteoporos Int 26:273\u2013279. https:\/\/doi.org\/10.1007\/s00198-014-2859-2","DOI":"10.1007\/s00198-014-2859-2"},{"key":"7941_CR43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","volume":"17","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807\u2013816. https:\/\/doi.org\/10.1007\/s00198-005-0065-y","journal-title":"Osteoporos Int"},{"key":"7941_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bone.2015.04.042","volume":"78","author":"AJ Feuer","year":"2015","unstructured":"Feuer AJ, Demmer RT, Thai A, Vogiatzi MG (2015) Use of selective serotonin reuptake inhibitors and bone mass in adolescents: an NHANES study. Bone 78:28\u201333. https:\/\/doi.org\/10.1016\/j.bone.2015.04.042","journal-title":"Bone"},{"key":"7941_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s10334-004-0033-0","volume":"16","author":"NR Bolo","year":"2004","unstructured":"Bolo NR, Hod\u00e9 Y, Macher J-P (2004) Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo. MAGMA 16:268\u2013276. https:\/\/doi.org\/10.1007\/s10334-004-0033-0","journal-title":"MAGMA"},{"key":"7941_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/157488611797579267","volume":"6","author":"V Boshra","year":"2011","unstructured":"Boshra V (2011) Evaluation of osteoporosis risk associated with chronic use of morphine, fentanyl and tramadol in adult female rats. Curr Drug Saf 6:159\u2013163. https:\/\/doi.org\/10.2174\/157488611797579267","journal-title":"Curr Drug Saf"},{"key":"7941_CR47","doi-asserted-by":"publisher","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2006) Fracture risk associated with the use of morphine and opiates. J Intern Med 260(1):76\u201387. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01667.x","DOI":"10.1111\/j.1365-2796.2006.01667.x"},{"key":"7941_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-8-43","volume":"8","author":"L Petrizzi","year":"2007","unstructured":"Petrizzi L, Mariscoli M, Valbonetti L et al (2007) Preliminary study on the effect of parenteral naloxone, alone and in association with calcium gluconate, on bone healing in an ovine \u201cdrill hole\u201d model system. BMC Musculoskelet Disord 8:43. https:\/\/doi.org\/10.1186\/1471-2474-8-43","journal-title":"BMC Musculoskelet Disord"},{"key":"7941_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112011","volume":"123","author":"P Shitole","year":"2021","unstructured":"Shitole P, Choubey A, Mondal P, Ghosh R (2021) Influence of low dose naltrexone on Raman assisted bone quality, skeletal advanced glycation end-products and nano-mechanical properties in type 2 diabetic mice bone. Mater Sci Eng C Mater Biol 123:112011. https:\/\/doi.org\/10.1016\/j.msec.2021.112011","journal-title":"Mater Sci Eng C Mater Biol"},{"key":"7941_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/IJPC.IJPC_167_19","volume":"26","author":"PN Jain","year":"2020","unstructured":"Jain PN, Chatterjee A (2020) A randomized placebo-controlled trial evaluating the analgesic effect of salmon calcitonin in refractory bone metastasis pain. Indian J Palliat Care 26:4\u20138. https:\/\/doi.org\/10.4103\/IJPC.IJPC_167_19","journal-title":"Indian J Palliat Care"},{"key":"7941_CR51","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299\u20131309. https:\/\/doi.org\/10.1093\/jnci\/djr242","journal-title":"J Natl Cancer Inst"},{"key":"7941_CR52","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e403","volume":"35","author":"YK Lee","year":"2020","unstructured":"Lee YK, Lee EG, Kim HY et al (2020) Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci 35:e403. https:\/\/doi.org\/10.3346\/jkms.2020.35.e403","journal-title":"J Korean Med Sci"},{"key":"7941_CR53","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141. https:\/\/doi.org\/10.1016\/S1470-2045(10)70257-6","journal-title":"Lancet Oncol"},{"key":"7941_CR54","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051\u20131057. https:\/\/doi.org\/10.1200\/JCO.2007.11.0726","journal-title":"J Clin Oncol"},{"key":"7941_CR55","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisd\u00f3ttir","year":"2004","unstructured":"Sverrisd\u00f3ttir A, Fornander T, Jacobsson H et al (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694\u20133699. https:\/\/doi.org\/10.1200\/JCO.2004.08.148","journal-title":"J Clin Oncol"},{"key":"7941_CR56","doi-asserted-by":"publisher","unstructured":"Kalder M, Kyvernitakis I, Albert US et al (2015) Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Osteoporos Int 26:353\u2013360. https:\/\/doi.org\/10.1007\/s00198-014-2955-3","DOI":"10.1007\/s00198-014-2955-3"},{"key":"7941_CR57","doi-asserted-by":"publisher","unstructured":"Miyashita H, Satoi S, Kuno T, et al (2020) Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat 181:279\u2013289. https:\/\/doi.org\/10.1007\/s10549-020-05640-3","DOI":"10.1007\/s10549-020-05640-3"},{"key":"7941_CR58","doi-asserted-by":"publisher","unstructured":"Lassemillante A-CM, SAR, Hooper JD, et al (2015) Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy Endocrine 50:344\u2013354. https:\/\/doi.org\/10.1007\/s12020-015-0536-7","DOI":"10.1007\/s12020-015-0536-7"},{"key":"7941_CR59","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","volume":"57","author":"BJ Kiratli","year":"2001","unstructured":"Kiratli BJ, Srinivas S, Perkash I, Terris MK (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127\u2013132. https:\/\/doi.org\/10.1016\/S0090-4295(00)00895-5","journal-title":"Urology"},{"key":"7941_CR60","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408\u20131418. https:\/\/doi.org\/10.1056\/NEJMoa1715546","journal-title":"N Engl J Med"},{"key":"7941_CR61","doi-asserted-by":"publisher","unstructured":"Fizazi K, Shore N, Tammela TL, et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380:1235\u20131246. https:\/\/doi.org\/10.1056\/NEJMoa1815671","DOI":"10.1056\/NEJMoa1815671"},{"key":"7941_CR62","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465\u20132474. https:\/\/doi.org\/10.1056\/NEJMoa1800536","journal-title":"N Engl J Med"},{"key":"7941_CR63","doi-asserted-by":"publisher","unstructured":"Hussain A, Tripathi A, Pieczonka C, et al (2021) Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24:290\u2013300. https:\/\/doi.org\/10.1038\/s41391-020-00296-y","DOI":"10.1038\/s41391-020-00296-y"},{"key":"7941_CR64","doi-asserted-by":"publisher","unstructured":"Poon Y, Pechlivanoglou P, Alibhai SMH, et al (2018) Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 121:17\u201328. https:\/\/doi.org\/10.1111\/bju.14015","DOI":"10.1111\/bju.14015"},{"key":"7941_CR65","doi-asserted-by":"publisher","unstructured":"Gillessen S, Choudhury A, Rodriguez-Vida A, et al (2021) Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis. J Clin Oncol 39:5002\u20135002. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5002","DOI":"10.1200\/JCO.2021.39.15_suppl.5002"},{"key":"7941_CR66","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","volume":"41","author":"S D\u2019Oronzo","year":"2015","unstructured":"D\u2019Oronzo S, Stucci S, Tucci M, Silvestris F (2015) Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev 41:798\u2013808. https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.003","journal-title":"Cancer Treat Rev"},{"key":"7941_CR67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1634\/theoncologist.2012-0416","volume":"18","author":"C Stavraka","year":"2013","unstructured":"Stavraka C, Maclaran K, Gabra H et al (2013) A study to evaluate the cause of bone demineralization in gynecological cancer survivors. Oncologist 18:423\u2013429. https:\/\/doi.org\/10.1634\/theoncologist.2012-0416","journal-title":"Oncologist"},{"key":"7941_CR68","first-page":"47","volume":"24","author":"R Swaminathan","year":"2003","unstructured":"Swaminathan R (2003) Magnesium metabolism and its disorders. Clin Biochem Rev 24:47\u201366","journal-title":"Clin Biochem Rev"},{"key":"7941_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-015-0266-z","volume":"13","author":"MD Wissing","year":"2015","unstructured":"Wissing MD (2015) Chemotherapy- and irradiation-induced bone loss in adults with solid tumors. Curr Osteoporos Rep 13:140. https:\/\/doi.org\/10.1007\/s11914-015-0266-z","journal-title":"Curr Osteoporos Rep"},{"key":"7941_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773946","volume":"13","author":"SR Greisen","year":"2022","unstructured":"Greisen SR, Kragstrup TW, Thomsen JS et al (2022) The programmed death-1 pathway counter-regulates inflammation-induced osteoclast activity in clinical and experimental settings. Front Immunol 13:773946. https:\/\/doi.org\/10.3389\/fimmu.2022.773946","journal-title":"Front Immunol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07941-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07941-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07941-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:02:00Z","timestamp":1792270920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07941-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7941"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07941-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}